Cargando…
Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis
Although therapies of cancer are advancing, it remains challenging for therapeutics to reach the sites of metastasis, which accounts for majority of cancer associated death. In this study, we have developed a strategy that guides an anti-programmed cell death-ligand 1 (aPDL1) antibody to accumulate...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119987/ https://www.ncbi.nlm.nih.gov/pubmed/33986264 http://dx.doi.org/10.1038/s41467-021-22674-3 |
_version_ | 1783691971274997760 |
---|---|
author | Li, Hongjun Wang, Zejun Chen, Zhaowei Ci, Tianyuan Chen, Guojun Wen, Di Li, Ruoxin Wang, Jinqiang Meng, Huan Bryan Bell, R. Gu, Zhifeng Dotti, Gianpietro Gu, Zhen |
author_facet | Li, Hongjun Wang, Zejun Chen, Zhaowei Ci, Tianyuan Chen, Guojun Wen, Di Li, Ruoxin Wang, Jinqiang Meng, Huan Bryan Bell, R. Gu, Zhifeng Dotti, Gianpietro Gu, Zhen |
author_sort | Li, Hongjun |
collection | PubMed |
description | Although therapies of cancer are advancing, it remains challenging for therapeutics to reach the sites of metastasis, which accounts for majority of cancer associated death. In this study, we have developed a strategy that guides an anti-programmed cell death-ligand 1 (aPDL1) antibody to accumulate in metastatic lesions to promote anti-tumour immune responses. Briefly, we have developed a combination in which Vadimezan disrupts tumour blood vessels of tumour metastases and facilitates the recruitment and activation of adoptively transferred aPDL1-conjugated platelets. In situ activated platelets generate aPDL1-decorated platelet-derived microparticles (PMP) that diffuse within the tumour and elicit immune responses. The proposed combination increases 10-fold aPDL1 antibody accumulation in lung metastases as compared to the intravenous administration of the antibody and enhances the magnitude of immune responses leading to improved antitumour effects. |
format | Online Article Text |
id | pubmed-8119987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-81199872021-05-18 Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis Li, Hongjun Wang, Zejun Chen, Zhaowei Ci, Tianyuan Chen, Guojun Wen, Di Li, Ruoxin Wang, Jinqiang Meng, Huan Bryan Bell, R. Gu, Zhifeng Dotti, Gianpietro Gu, Zhen Nat Commun Article Although therapies of cancer are advancing, it remains challenging for therapeutics to reach the sites of metastasis, which accounts for majority of cancer associated death. In this study, we have developed a strategy that guides an anti-programmed cell death-ligand 1 (aPDL1) antibody to accumulate in metastatic lesions to promote anti-tumour immune responses. Briefly, we have developed a combination in which Vadimezan disrupts tumour blood vessels of tumour metastases and facilitates the recruitment and activation of adoptively transferred aPDL1-conjugated platelets. In situ activated platelets generate aPDL1-decorated platelet-derived microparticles (PMP) that diffuse within the tumour and elicit immune responses. The proposed combination increases 10-fold aPDL1 antibody accumulation in lung metastases as compared to the intravenous administration of the antibody and enhances the magnitude of immune responses leading to improved antitumour effects. Nature Publishing Group UK 2021-05-13 /pmc/articles/PMC8119987/ /pubmed/33986264 http://dx.doi.org/10.1038/s41467-021-22674-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Li, Hongjun Wang, Zejun Chen, Zhaowei Ci, Tianyuan Chen, Guojun Wen, Di Li, Ruoxin Wang, Jinqiang Meng, Huan Bryan Bell, R. Gu, Zhifeng Dotti, Gianpietro Gu, Zhen Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis |
title | Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis |
title_full | Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis |
title_fullStr | Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis |
title_full_unstemmed | Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis |
title_short | Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis |
title_sort | disrupting tumour vasculature and recruitment of apdl1-loaded platelets control tumour metastasis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119987/ https://www.ncbi.nlm.nih.gov/pubmed/33986264 http://dx.doi.org/10.1038/s41467-021-22674-3 |
work_keys_str_mv | AT lihongjun disruptingtumourvasculatureandrecruitmentofapdl1loadedplateletscontroltumourmetastasis AT wangzejun disruptingtumourvasculatureandrecruitmentofapdl1loadedplateletscontroltumourmetastasis AT chenzhaowei disruptingtumourvasculatureandrecruitmentofapdl1loadedplateletscontroltumourmetastasis AT citianyuan disruptingtumourvasculatureandrecruitmentofapdl1loadedplateletscontroltumourmetastasis AT chenguojun disruptingtumourvasculatureandrecruitmentofapdl1loadedplateletscontroltumourmetastasis AT wendi disruptingtumourvasculatureandrecruitmentofapdl1loadedplateletscontroltumourmetastasis AT liruoxin disruptingtumourvasculatureandrecruitmentofapdl1loadedplateletscontroltumourmetastasis AT wangjinqiang disruptingtumourvasculatureandrecruitmentofapdl1loadedplateletscontroltumourmetastasis AT menghuan disruptingtumourvasculatureandrecruitmentofapdl1loadedplateletscontroltumourmetastasis AT bryanbellr disruptingtumourvasculatureandrecruitmentofapdl1loadedplateletscontroltumourmetastasis AT guzhifeng disruptingtumourvasculatureandrecruitmentofapdl1loadedplateletscontroltumourmetastasis AT dottigianpietro disruptingtumourvasculatureandrecruitmentofapdl1loadedplateletscontroltumourmetastasis AT guzhen disruptingtumourvasculatureandrecruitmentofapdl1loadedplateletscontroltumourmetastasis |